US stock futures flounder amid tech weakness, Fed caution
In a recent SEC filing, Know Labs, Inc., a company specializing in measuring and controlling devices, announced the amendment of its senior secured convertible redeemable notes. The Seattle-based company, listed on NYSE American under the ticker NYSE:KNW, has extended the maturity date of its debt from September 30, 2024, to September 30, 2025.
The amendments, approved on Monday, October 22, 2024, involve notes held by Ronald P. Erickson and affiliated entities. Alongside the extension of the due date, the interest rate on these notes will increase from 6% to 8%. This adjustment reflects a renegotiation of the terms initially set in the promissory note dated January 31, 2018.
Know Labs, Inc. has not disclosed the reasons for the amendments or the total value of the debt affected by this change. However, the adjustment in the interest rate suggests a revised cost of capital for the company, which could impact its financial strategy moving forward.
This financial maneuver comes at a time when many companies are reassessing their debt structures amid fluctuating market conditions. The filing indicates that Know Labs is actively managing its liabilities to align with its operational needs and long-term objectives.
This news is based on a press release statement.
In other recent news, Know Labs, Inc., a developer of non-invasive diagnostic technology, has reported several significant developments. The company has seen changes in its leadership team, with the appointment of John Cronin as Interim Chief Technology Officer and Dominic Klyve, Ph.D., as Chief Science Officer. These appointments are expected to foster the company's technological advancement.
Additionally, Know Labs announced a Q3 net loss of $4.1 million for fiscal year 2024, an improvement from the previous year, and decreased research and development expenses. The company also raised $1.655 million in a recent financing round, with Boustead Securities, LLC and The Benchmark Company, LLC serving as advisors.
Furthermore, Know Labs has been notified of non-compliance with NYSE American continued listing standards due to reported losses over recent fiscal years. The company is required to submit a compliance plan by October 27, 2024, to meet the exchange's listing standards by March 27, 2026.
Other recent developments include making progress with its non-invasive glucose monitor, KnowU, which is currently in clinical trials and awaiting FDA clearance.
Despite reporting negative shareholder equity for the quarter, Know Labs has completed a capital raise and is taking measures to improve this.
These are recent developments, reflecting Know Labs' ongoing efforts to manage its financial challenges while working towards enhancing shareholder value and corporate visibility.
InvestingPro Insights
Recent InvestingPro data sheds light on Know Labs' financial situation, providing context to the company's decision to amend its senior secured convertible redeemable notes. The company's market capitalization stands at a modest $22.98 million, reflecting its small-cap status.
InvestingPro Tips indicate that Know Labs is "quickly burning through cash" and that "short term obligations exceed liquid assets." These factors likely contributed to the company's decision to extend the maturity date of its debt and increase the interest rate, as it seeks to manage its financial obligations.
The company's stock performance has been challenging, with InvestingPro data showing a significant 67.14% price decline over the past six months. This downward trend aligns with another InvestingPro Tip noting that the "stock has taken a big hit over the last six months."
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips for Know Labs, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.